Summary
Updated Aug 30, 2026
Andrew James King is Chief Scientific Officer & Head of Research and Development of Jade Biosciences, Inc. (JBIO). 1 SEC Form 4 filing on record, dated 14 February 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Andrew James King has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Andrew James King's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Mark J. Tarr - $38.47M of EHC open-market activity in the last 12 months
- Helen Torley - $37.86M of HALO open-market activity in the last 12 months
- Kevin Charles Gorman - $37.82M of NBIX open-market activity in the last 12 months
- Emily M. Leproust - $35.18M of TWST open-market activity in the last 12 months
- Tactic Pharma LLC - $35.00M of MNPR open-market activity in the last 12 months
- Roelof Botha - $34.89M of NTRA open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Andrew James King?
Andrew James King is a corporate insider, tracked as Chief Scientific Officer & Head of Research and Development of Jade Biosciences, Inc. (JBIO). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Andrew James King last file a Form 4?
The only primary Form 4 on record is dated 14 February 2026.
Where can I see all of Andrew James King's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Andrew James King and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
